NCT05757804招募中不适用
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Complete PET imaging
研究概览
简要总结
To explore the diagnostic value of 18F-0502B brain imaging for α-Syn protein-related diseases in patients with PD. To evaluate the imaging range of α-Syn protein density in patients with α-Syn protein-related diseases and to assess the level of abnormal α-Syn protein deposition by PET imaging with this PET tracer, and its safety in human studies.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 60 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Non-disease controls:
- •Age between 60 and 80 years; gender is not limited.
- •Normal motor function as determined by the investigator through testing; UPDRS score of
- •No neurological disease, major chronic disease, malignancy or acute infectious disease as confirmed by the investigator.
- •Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
- •Blood count: white blood cell count (WBC) 4-10×109/L; platelets (PLT) 100-300×109/L; hemoglobin (HB) 120-160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range. Electrocardiogram: no significant abnormalities.
- •No neurological disorders, major chronic diseases, malignant tumors or acute infectious diseases as confirmed by the investigator, no family history of neurodegenerative movement disorders, no family history of neurological disorders related to movement disorders.
- •Be willing and able to cooperate with all the projects of this study.
- •PD patients:
- •Age between 60 and 80 years old; gender is not limited.
- •Patients meet the diagnostic criteria for PD (2015 version of the diagnostic guidelines for PD developed by the International Movement Disorders Society MDS), mild-moderate patients (H&Y classification 1-3 inclusive).
- •Brain MRI supports the diagnosis of PD and there is no other evidence of neurological disease.
- •No neurological disease, major chronic disease, malignancy or acute infectious disease as confirmed by the investigator.
- •Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
- •Blood count: white blood cell count (WBC) 4-10×109/L; platelets (PLT) 100-300×109/L; hemoglobin (HB) 120-160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range. Electrocardiogram: no significant abnormalities.
- •No neurological disorders, major chronic diseases, malignant tumors or acute infectious diseases as confirmed by the investigator, no family history of neurodegenerative movement disorders, no family history of neurological disorders related to movement disorders.
- •Be willing and able to cooperate with all the projects of this study.
- •DLB patients:
- •Age was between 60 and 80 years; gender was not restricted.
- •Patients meet the diagnostic criteria for probable and likely Lewy body dementia developed by the International Working Group on Dementia with Lewy Bodies meeting
- •The diagnosis of DLB was supported by brain MRI and there was no other evidence of neurological disease.
- •No neurological disease, major chronic illness, malignancy, or acute infectious disease as confirmed by the investigator.
- •Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
- •Blood count: white blood cell count (WBC) 4-10×109/L; platelets (PLT) 100-300×109/L; hemoglobin (HB) 120-160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range. Electrocardiogram: no significant abnormalities.
- •No neurological disorders, major chronic diseases, malignant tumors or acute infectious diseases as confirmed by the investigator, no family history of neurodegenerative movement disorders, no family history of neurological disorders related to movement disorders.
- •Be willing and able to cooperate with all the projects of this study.
- •MSA patients:
- •Age was between 60 and 80 years old; gender was not limited.
- •Patients meet the diagnostic criteria of the newly released 2022 MSA diagnostic consensus
- •Brain MRI supported the diagnosis of MSA and no other evidence of neurological disease.
- •No neurological disease, major chronic disease, malignancy, or acute infectious disease as confirmed by the investigator
- •Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
- •Blood count: white blood cell count (WBC) 4-10×109/L; platelets (PLT) 100-300×109/L; hemoglobin (HB) 120-160 g/L; renal function: serum creatinine less than or equal to the upper limit of the normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of the normal range. Electrocardiogram: no significant abnormalities.
- •No neurological disorders, major chronic diseases, malignant tumors or acute infectious diseases as confirmed by the investigator, no family history of neurodegenerative movement disorders, no family history of neurological disorders related to movement disorders.
- •Be willing and able to cooperate with all the projects of this study.
排除标准
- •Subjects meeting any of the following criteria will be excluded from the study:
- •Suffering from other serious neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor endocrine, respiratory system, immune deficiency and other serious diseases.
- •In the past year, in addition to participating in the expected radiation exposure of this clinical study, have participated in other research programs or clinical care, resulting in radiation exposure exceeding the effective dose of 50 mSv.
- •Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
- •The candidate subject has received major surgery or received experimental drug or device treatment (with unclear effect or safety) within 1 month
结局指标
主要结局
Complete PET imaging
时间窗: 90mins from time of injection
Assessment of PET/CT imaging to detect α-synuclein in patients with α-synuclein-related Diseases
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy PatientsRapid Eye Movement Sleep Behavior Disorderα-synucleinopathyParkinson's Disease (PD)PETMultiple System AtrophyNCT06738862Ruijin Hospital55
招募中
早期 1 期
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid TumorTumor, SolidNCT06126705Affiliated Hospital of North Sichuan Medical College60
招募中
不适用
Beta Amyloid PET/CT in Various Aβ-Related DiseaseAmyloidBeta-AmyloidNeurodegenerative DiseasesNCT06725706Tianjin Medical University500
已完成
2 期
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast CancerBreast Cancer InvasiveNCT06695039Asan Medical Center71
招募中
不适用
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-FluselenamylAlzheimer DiseaseNCT06439992Washington University School of Medicine60